Association between endogenous sex steroid hormones and inflammatory biomarkers in US men

Andrology

Volumn 1, Issue 6, 2013, Pages 919-928

  Tsilidis, K K ^a   Rohrmann, S ^b   Mcglynn, K A ^c   Nyante, S J ^c   Lopez, D S ^d   Bradwin, G ^e   Feinleib, M ^f   Joshu, C E ^f   Kanarek, N ^f,g   Nelson, W G ^f,g,h   Selvin, E ^f,i   Platz, E A ^f,g,h,i  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

C reactive protein; Cross sectional study; Estradiol; Testosterone; White blood cell

Indexed keywords

ANDROSTANOLONE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; GLUCURONIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BASOPHIL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; EOSINOPHIL COUNT; ESTRADIOL BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LEISURE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SMOKING; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDY; ESTRADIOL; TESTOSTERONE; WHITE BLOOD CELL;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ESTRADIOL; GONADAL STEROID HORMONES; HUMANS; INFLAMMATION; LEUKOCYTE DISORDERS; LINEAR MODELS; MALE; NUTRITION SURVEYS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84886389619     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/j.2047-2927.2013.00129.x     Document Type: Article

References (46)

1. (1994). Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1, 1-407.
2. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT & Wittert GA. (2011) Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 96, 3007-3019.
3. Asirvatham AJ, Schmidt M, Gao B & Chaudhary J. (2006) Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinol 147, 257-271.
4. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA et al. (1995) Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95, 2886-2895.
5. Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H & Dandona P. (2006) Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 29, 2289-2294.
6. Brand JS, van der Schouw YT, Dowsett M, Folkerd E, Luben RN, Wareham NJ et al. (2012) Testosterone, SHBG and differential white blood cell count in middle-aged and older men. Maturitas 71, 274-278.
7. Centers for Disease Control and Prevention, National Center for Health Statistics (1999) National Health and Nutrition Examination Survey Laboratory Protocol. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/lab06_met_cotinine.pdf.
8. Centers for Disease Control and Prevention, National Center for Health Statistics (2000) National Health and Nutrition Examination Survey Laboratory Protocol. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l11_c_met_c_reactive_protein.pdf.
9. Ding EL, Song Y, Malik VS & Liu S. (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295, 1288-1299.
10. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87, 589-598.
11. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ & Saad F. (2010) Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 73, 602-612.
12. Kaplan SA, Johnson-Levonas AO, Lin J, Shah AK & Meehan AG. (2010) Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. Aging Male 13, 108-112.
13. Kapoor D, Clarke S, Stanworth R, Channer KS & Jones TH. (2007) The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156, 595-602.
14. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R et al. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132-140.
15. Khosla S, Atkinson EJ, Dunstan CR & O'Fallon WM. (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87, 1550-1554.
16. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T et al. (2003) Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111, 1651-1664.
17. Kovacs A, Henriksson P, Hamsten A, Wallen H, Bjorkegren J & Tornvall P. (2005) Hormonal regulation of circulating C-reactive protein in men. Clin Chem 51, 911-913.
18. Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV & McKinlay JB. (2010) Association of sex hormones and C-reactive protein levels in men. Clin Endocrinol (Oxf) 72, 527-533.
19. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R et al. (2003) Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149, 601-608.
20. MacDonald PC, Madden JD, Brenner PF, Wilson JD & Siiteri PK. (1979) Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 496, 905-916.
21. Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda GP et al. (2006) Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab 91, 345-347.
22. Maggio M, Ceda GP, Lauretani F, Bandinelli S, Metter EJ, Artoni A et al. (2009) Estradiol and inflammatory markers in older men. J Clin Endocrinol Metab 94, 518-522.
23. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS & Jones TH. (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89, 3313-3318.
24. Mauduit C, Gasnier F, Rey C, Chauvin MA, Stocco DM, Louisot P et al. (1998) Tumor necrosis factor-alpha inhibits leydig cell steroidogenesis through a decrease in steroidogenic acute regulatory protein expression. Endocrinology 139, 2863-2868.
25. Morley JE, Patrick P& Perry HM 3rd. (2002) Evaluation of assays available to measure free testosterone. Metabolism 51, 554-559.
26. Nakhai Pour HR, Grobbee DE, Muller M & van der Schouw YT. (2007) Association of endogenous sex hormone with C-reactive protein levels in middle-aged and elderly men. Clin Endocrinol (Oxf) 66, 394-398.
27. Nakhai-Pour HR, Grobbee DE, Emmelot-Vonk MH, Bots ML, Verhaar HJ & van der Schouw YT. (2007). Oral testosterone supplementation and chronic low-grade inflammation in elderly men: a 26-week randomized, placebo-controlled trial. Am Heart J 154, 1228. e1221-e1227.
28. Nelson WG, De Marzo AM, DeWeese TL & Isaacs WB. (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172, S6-S12.
29. Ng MK, Liu PY, Williams AJ, Nakhla S, Ly LP, Handelsman DJ et al. (2002) Prospective study of effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol 22, 1136-1141.
30. Nyante SJ, Graubard BI, Li Y, McQuillan GM, Platz EA, Rohrmann S et al. (2012) Trends in sex hormone concentrations in US males: 1988-1991 to 1999-2004. Int J Androl 35, 456-466.
31. Platz EA & De Marzo AM. (2004) Epidemiology of inflammation and prostate cancer. J Urol 171, S36-S40.
32. Platz EA & Giovannucci E. (2004) The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92, 237-253.
33. Roddam AW, Allen NE, Appleby P & Key TJ. (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100, 170-183.
34. Rohrmann S, Platz EA, Selvin E, Shiels MS, Joshu CE, Menke A et al. (2011a) The prevalence of low sex steroid hormone concentrations in men in the Third National Health and Nutrition Examination Survey (NHANES III). Clin Endocrinol (Oxf) 75, 232-239.
35. Rohrmann S, Shiels MS, Lopez DS, Rifai N, Nelson WG, Kanarek N et al. (2011b) Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes Control 22, 1141-1151.
36. Schneider HJ, Sievers C, Klotsche J, Bohler S, Pittrow D, Lehnert H et al. (2009) Prevalence of low male testosterone levels in primary care in Germany: cross-sectional results from the DETECT study. Clin Endocrinol (Oxf) 70, 446-454.
37. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA et al. (2002) The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87, 136-143.
38. Sodergard R, Backstrom T, Shanbhag V & Carstensen H. (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16, 801-810.
39. Tang YJ, Lee WJ, Chen YT, Liu PH, Lee MC & Sheu WH. (2007) Serum testosterone level and related metabolic factors in men over 70 years old. J Endocrinol Invest 30, 451-458.
40. Taxel P, Luthra P, Fall PM & Dauser D. (2008) The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer. Aging Male 11, 71-75.
41. Tengstrand B, Carlstrom K & Hafstrom I. (2002) Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology (Oxford) 41, 285-289.
42. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G & Kaufman JM. (2003) Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166, 95-102.
43. Vermeulen A, Verdonck L & Kaufman JM. (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84, 3666-3672.
44. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P et al. (2012) Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 214, 31-43.
45. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B & Jialal I. (2003) Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 41, 1358-1363.
46. Zhang Y, Gao Y, Tan A, Yang X, Zhang H, Zhang S et al.(2012) Endogenous sex hormones and C-reactive protein in healthy Chinese men. Clin Endocrinol (Oxf) 78, 60-66.